31.1 C
Vientiane
Saturday, July 5, 2025
spot_img
Home Blog Page 1005

SERES Leads Chinese EV Innovation at Davos, Championing Global Collaboration for the Intelligent Age

CHONGQING, China, Jan. 27, 2025 /PRNewswire/ — During the World Economic Forum’s 2025 annual meeting held from January 20-24 in Davos-Klosters, Switzerland, nearly 3,000 representatives from 130 countries and regions discussed the theme “Collaboration for the Intelligent Age,” exploring topics such as reimagining growth and industries in the intelligent era. SERES Vice President Kang Bo was the sole Chinese new energy vehicle enterprise representative invited to attend and participate in multiple forum activities.

Media reports
Media reports

In today’s globalized landscape, open collaboration has become essential. By sharing resources and expertise across industries, innovative business models and development approaches are emerging, enabling high-quality collaboration in the intelligent age. Kang Bo emphasized that sector boundaries are becoming increasingly fluid, with cross-industry collaboration becoming critical. SERES has substantially benefited from this collaborative approach, building partnerships with global automotive suppliers and leading technology companies to enhance its products’ intelligence and connectivity. The company now shares its powertrain technology with 12 partners worldwide, driving collective progress in the automotive industry.

Media reports
Media reports

“Advancements in new quality productive forces have propelled China’s new energy vehicle industry to new heights,” Kang Bo highlighted. Domestic automakers have made significant strides in core competencies, developing cutting-edge technologies in electric powertrains, artificial intelligence, new materials, and advanced manufacturing processes. These innovations have strengthened the entire industry value chain, positioning Chinese vehicle enterprises competitively in the high-end market. SERES stands as a prime example of high-quality innovation, with its brand image and perceived value continuously evolving.

In 2024, SERES achieved remarkable results, with annual new energy vehicle sales exceeding 420,000 units, representing a year-on-year growth of over 182%. Kang Bo believes the core competitiveness of intelligent vehicles lies in Software-Defined Vehicles (SDV). Through continuous over-the-air (OTA) updates, they provide users with an innovative and frequently renewed driving experience, enhancing both software features and overall hardware performance throughout the vehicle’s lifecycle.

SERES has pioneered innovative technology in intelligent manufacturing, establishing a globally benchmarked Super Factory in Chongqing. The facility, housing over 3,000 robots, achieves 100% automation in critical processes and comprehensive vehicle inspections, significantly boosting production efficiency and product quality. The company has implemented 10,000-ton integrated die-casting technology, dramatically reducing component count and enhancing overall vehicle quality.

 

FOUR POINTS BY SHERATON BANGKOK, SUKHUMVIT 22 OPENS ITS DOORS IN THE HEART OF THE THAI CAPITAL

 New Hotel to Elevate Business and Leisure Stays with Striking Vintage Design and Modern Amenities, Surrounded by World-Class Attractions in the Commercial Center of Bangkok

BANGKOK, Jan. 27, 2025 /PRNewswire/ — Four Points by Sheraton, part of Marriott Bonvoy’s portfolio of over 30 extraordinary hotel brands, proudly announces the opening of Four Points by Sheraton Bangkok, Sukhumvit 22. Redefining urban hospitality, this stylish new hotel combines timeless design concept with seamless connectivity and modern amenities to provide guests with a comfortable, convenient and inspiring stay in the beating heart of Thailand’s capital city.

FOUR POINTS BY SHERATON BANGKOK, SUKHUMVIT 22 OPENS ITS DOORS IN THE HEART OF THE THAI CAPITAL
FOUR POINTS BY SHERATON BANGKOK, SUKHUMVIT 22 OPENS ITS DOORS IN THE HEART OF THE THAI CAPITAL

“We are excited to welcome a new Four Points by Sheraton property to Bangkok’s buzzing Sukhumvit district,” said Brad Edman, Market Vice President – Thailand, Cambodia & Myanmar, Marriot International. “This hotel will resonate with guests who want to kick back, relax and explore Bangkok’s many attractions. With its unique design, genuine hospitality and great value, Four Points by Sheraton Bangkok, Sukhumvit 22 will meet the rising demand from business and leisure travelers in this dynamic metropolis.”

Four Points by Sheraton Bangkok, Sukhumvit 22 is strategically located in Bangkok’s bustling Sukhumvit district, just 300 meters from The EmDistrict – a major retail and lifestyle haven comprising three world-class malls, The Emporium, EmQuartier and EmSphere, plus UOB Live, Southeast Asia’s newest live entertainment venue – and surrounded by corporate offices, cultural attractions, and the city’s vibrant nightlife. Queen Sirikit National Convention Centre (QSNCC) is less than 3km away, and the BTS SkyTrain stations at Phrom Phong and Asoke, and MRT Sukhumvit put the entire city within easy reach.

The hotel’s striking interior concept was created by Pomme Chan, the iconic Thai designer, and blends modern urban and industrial design with vintage elements, including old shophouse gates, chandeliers and street photography. With original artworks and installations by Bangkok Street artists, this hotel captures the transformation of the Sukhumvit area from the mid-20th Century to the present day.

The 333 rooms & suites are restful retreats where travelers can take a break from the city’s fast-paced energy. With soothing tones and textures, comfortable king or twin beds, dedicated workspaces with integrated USB ports, Bluetooth alarm clocks with wireless charging, fast Wi-Fi, 55″ LED TVs, and refreshing bathrooms with rain showers, every guest can unwind and stay productive.

Every day can start with breakfast at The Mesh, the casual all-day dining destination which also sets the scene for daytime bites and business lunches. Then as evening falls, this inviting venue transforms into a contemporary beer house and sports bar, where hotel guests and local residents can come together and sip Bangkok’s BestBrews™, in line with Four Points’ signature craft beer program, along with a wide range of freshly prepared Thai and international dishes.

The Mesh Lounge is a flexible and fully connected space for corporate meetings and social events with up to 25 guests, while the boardrooms can host inspiring sessions with up to 10 people, all equipped with state-of-the-art technology. When visitors are not working or exploring the city, they can work out at the 24/7 fitness center or chill out at the rooftop pool, with stunning views of Bangkok’s skyline.

“At Four Points by Sheraton Bangkok, Sukhumvit 22, we aim to redefine urban hospitality with timeless design, convenient amenities and thoughtful service,” said Peter Feran, General Manager, Four Points by Sheraton Bangkok, Sukhumvit 22. “We are delighted to welcome guests to this dynamic part of Bangkok and provide them with everything they need to rest, relax and stay connected, all underpinned by the timeless standards of the Four Points by Sheraton brand.”

The hotel participates in Marriott Bonvoy – the award-winning travel program from Marriott International – allowing members to earn and redeem points for their stay at the new hotel, and at other hotels and resorts across Marriott Bonvoy’s portfolio of extraordinary hotel brands. With the Marriott Bonvoy app, members enjoy a level of personalization that allows them to travel with peace of mind.

For more information or to book your stay, please visit www.fourpointsbangkoksukhumvit22.com.

About Four Points by Sheraton

Four Points by Sheraton is a global brand with over 310 hotels in over 45 countries and territories. At Four Points, travel is reinvented where timeless classics are woven with modern details, paired with genuine service in a casual environment—all around the world. Four Points hotels can be found in the heart of urban centers, near the beach, by the airport, or in the suburbs. Each hotel offers a familiar place to kick back and relax with an authentic sense of the local, where guests can watch sports and enjoy the brand’s Best Brews® program. Four Points is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including free nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com. To learn more about Four Points, visit us online.

About Marriott Bonvoy®

Marriott Bonvoy, Marriott International’s portfolio of more than 30 hotel brands and 10,000 global destinations, offers renowned hospitality in the most memorable locations around the world. The award-winning travel program and marketplace gives members access to transformative, eye-opening experiences around the corner and across the globe. To enroll for free or for more information about Marriott Bonvoy, visit marriottbonvoy.com. To download the Marriott app, go here. Travelers can also connect with Marriott Bonvoy on Facebook, X, Instagram, and TikTok.

Shanghai Lights Up in Celebration of UNESCO Recognition of China’s Spring Festival as an Intangible Cultural Heritage

Shanghai Invites the World to Celebrate Its Rich Heritage during the Spring Festival Celebrations

SHANGHAI, Jan. 27, 2025 /PRNewswire/ — On December 4, 2024, the United Nations Educational, Scientific and Cultural Organization (UNESCO) added China’s Spring Festival to its Representative List of the Intangible Cultural Heritage of Humanity. The recognition celebrates the Spring Festival’s significant role in fostering social practices and communal spirit as the Chinese people welcome their traditional new year. The designation will further boost Shanghai as a must-visit destination during this year’s Spring Festival celebrations.


Shanghai is hosting a series of exciting events that highlight this rich cultural heritage. The city’s renowned Shanghai Lantern Festival, a tradition with a history that spans more than two millennia, will illuminate the festivities. This year, the festival draws inspiration from the ancient “Classic of Mountains and Seas,” featuring the theme “The Beauty of All Things, the Wonder of Existence.” Visitors to the Yuyuan Lantern Festival can expect an enchanting experience with displays that transform the area into a mythical jungle paradise adorned with fluttering butterflies, vibrant flowers, lush forests, and winding snakes.


Moreover, historic locales within Shanghai, including Nanxiang, Luodian in Baoshan, Fengjing in Jinshan, and Qingxi Old Street, will each present their unique interpretations of lantern art. The displays not only dazzle the senses but also pay homage to the enduring folk traditions that enrich China’s cultural tapestry. Throughout the Spring Festival period, over 200 performances, exhibitions, and interactive experiences will be showcased, providing a deep dive into the festive and communal atmosphere that characterizes this time of year.

The city of Shanghai extends a warm invitation to visitors from around the world to explore the cultural magnificence of the Spring Festival and the mesmerizing beauty of the Shanghai Lantern Festival. The celebration is a testament to the living heritage that UNESCO aims to protect and promote for future generations.

CStone Partners with SteinCares to Market Sugemalimab in Latin America

  • CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries.
  • This marks CStone’s third major global commercialization partnership for sugemalimab, with additional deals in Western Europe, Southeast Asia, Canada, and other regions anticipated soon. CStone has received marketing approval for sugemalimab in the EU, EEA countries (Iceland, Liechtenstein, and Norway), and the UK, while actively advancing regulatory submissions for additional indications.

SUZHOU, China, Jan. 27, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced a strategic commercialization partnership with SteinCares, a leading pharmaceutical company with over 40 years of experience and a strong presence in Latin America. Under this agreement, SteinCares will gain the commercialization rights for sugemalimab in 10 LATAM countries, including Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala and Ecuador.

As part of this collaboration, SteinCares will be responsible for the regulatory affairs and commercialization activities of sugemalimab in these regions. CStone will supply sugemalimab and will receive upfront, regulatory, and commercial milestone payments as well as revenue from product supply.

Dr. Jason Yang, CEO, President of R&D and Executive Director at CStone, stated, “Following our successful market entries in Central and Eastern Europe, Switzerland, as well as the Middle East and Africa, we are excited to announce another key milestone in the global expansion of sugemalimab. As the first anti-PD-L1 monoclonal antibody approved in both the EU and UK for first-line, all-comer, Stage IV non-small cell lung cancer (NSCLC), sugemalimab is well-positioned for success in Latin America. SteinCares’ extensive distribution network and deep marketing expertise will significantly enhance sugemalimab’s reach.

We are also actively discussing with international partners in Western Europe, Southeast Asia, and Canada, while advancing regulatory submissions for additional indications of sugemalimab. We are confident that these efforts will further unlock the therapeutic and commercial potential of sugemalimab, ultimately benefiting patients worldwide.”

Mitchell Waserstein, CEO of SteinCares, added: “This agreement with CStone represents a significant step forward in our mission to create healthcare opportunities for patients in LATAM. At SteinCares, we are committed to providing more Latin Americans with greater access to safe, innovative, and affordable therapies. With our extensive experience and established sales network across the region, we are confident in our ability to successfully commercialize sugemalimab in LATAM and make a meaningful impact on patients’ health and well-being.”

About Sugemalimab

The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs. Sugemalimab’s differentiated molecular design enables a dual mechanism of action that not only blocks PD-1/PD-L1 interaction, but also induces antibody dependent cellular phagocytosis (ADCP) by cross-linking PD-L1 expressing tumor cells with tumor associated macrophages (TAMs) without harming Effector T-cells. This differentiation has resulted in competitive efficacy/safety across a variety of tumor types.

The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications:

  • In combination with chemotherapy as first-line treatment of patients with metastatic squamous and non-squamous NSCLC;
  • For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy;
  • For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma;
  • In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC; and
  • In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with a PD-L1 expression (Combined Positive Score [CPS] ≥5).

The European Commission (EC) has approved sugemalimab (brand name: Cejemly®) in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations.

The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has approved the marketing authorization application for sugemalimab in combination with platinum-based chemotherapy for first-line treatment of metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations.

About CStone 

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 17 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.

IR contact: ir@cstonepharma.com
PR contact: pr@cstonepharma.com

About SteinCares

SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars, plasma-derived therapies and complex generics. With more than 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region.

For more information, visit http://www.steincares.com/ or follow the company on LinkedIn.

Forward-looking statements 

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

MRC Secretariat Welcomes New Leadership

CEO Busadee Santipitaks (Photo: MRC)

Busadee Santipitaks has officially taken on her role as the first female and fourth Riparian Chief Executive Officer of the Mekong River Commission (MRC) Secretariat. Her three-year term began on 17 January. During this time, she will oversee the organization’s work from its headquarters in Vientiane, Laos, and the Flood and Drought Management Centre in Phnom Penh, Cambodia, from 2025 to 2027.

NetEase Cloud Music and SM Entertainment Reach Preliminary Agreement to Continue Music Streaming

HANGZHOU, China, Jan. 27, 2025 /PRNewswire/ — On January 25, 2025, NetEase Cloud Music, a major player in China’s music streaming market, announced a crucial development on Friday in its ongoing copyright renewal discussions with SM Entertainment. The breakthrough agreement will keep the South Korean company’s music catalog available to fans past the impending January 31 deadline, allowing for extended negotiations.

The announcement, headlined “Latest Development in SM Copyright Renewal,” comes as a relief to countless fans who had previously faced the prospect of losing access to their favorite K-POP tracks. According to NetEase Cloud Music, the “overwhelming support and earnest pleas from fans” played a pivotal role in bringing the two companies to the negotiating table.

Just a day earlier, NetEase Cloud Music had issued a somber notice to fans warning that SM Entertainment’s unilateral decision to not renew the copyright could result in the removal of all its songs from the streaming service. The potential loss had sparked heated discussions online, with related hashtags trending on Weibo and other social media platforms, drawing significant public attention.

In its latest release, NetEase Cloud Music reaffirmed its dedication to forging a “longer-term and more stable copyright cooperation” with SM Entertainment, highlighting its sincerity in negotiations.

Vientiane-Pakse Bus Crash Leaves 1 Dead, 43 Injured

Vientiane-Pakse Bus Crash Leaves 1 Dead, 43 Injured
Medical officers and residents gather to observe and rescue the victims of the road accident (photo credit: Lao Phatthana Newspaper)

A bus traveling from Vientiane to Pakse crashed into a tree on 26 January in Phudao Chengyai village, Lakonpheng district, Salavanh, resulting in 43 reported injuries and one fatality, according to Lao media.  

Arab Health 2025|Yuwell Medical Announces Strategic Investment and Partnership with Inogen in Respiratory Health

DUBAI, UAE, Jan. 27, 2025 /PRNewswire/ — On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai, and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration.

Alex WU, Chairman of Yuwell Medical, giving the speech
Alex WU, Chairman of Yuwell Medical, giving the speech

Speaking at the Yuwell Medical 2025 Global Core Partner Conference, Alex WU, Chairman of Yuwell Medical, stated that as a leading enterprise in China’s home medical device industry, Yuwell will rely on internal growth and external mergers and acquisitions to promote internationalisation. The company has updated its new vision for the next five years: to become top three companies in the global home medical health market in the mid-to-long term. Among them, respiratory treatment solutions, diabetes care, and emergency service solutions are the three key strategic sectors. The company will further strengthen its globalization strategy from three aspects: organizational structure expansion, recruitment of outstanding overseas talents product R&D innovation, and supply chain integration innovation.

He further emphasized, “In the process of realizing the new vision, Yuwell will work hand in hand with global partners to provide users with more competitive products and better health solutions.”

During the conference, Yuwell Medical and the American company Inogen formalized their collaboration by signing a strategic investment and cooperation memorandum, further deepening their partnership in the respiratory segment.

Yuwell Medial and Inogen formalized a strategic investment and cooperation
Yuwell Medial and Inogen formalized a strategic investment and cooperation

As one of the world’s largest manufacturers of oxygen concentrators, Yuwell Medical is widely recognized for its strong R&D capabilities and advanced manufacturing capabilities.

Inogen, a leading U.S. manufacturer of oxygen concentrators, brings extensive experience in portable oxygen concentrator technology. Yuwell, through its whole-owned subsidiary Yuwell (Hong Kong) Holdings Limited, has agreed to invest approximately $27.2 million in Inogen, representing 9.9% of the outstanding shares of Inogen’s common stock upon closing of this investment.

The two companies seek to upgrade devices technology through deepened collaboration. By combining their expertise and brand in their respective industry segments and geographies, Yuwell and Inogen agree to carry out in-depth strategic cooperation based on business synergy in four aspects: international distribution business, trademark licensing and distribution business, joint research and development, and supply chain optimization.

Yuwell Medical and Inogen are excited to build a long-term strategic partnership, ready to take advantage of emerging opportunities in today’s market. Together, they aim to enhance their international competitiveness and deliver innovative products that improve lives worldwide.

Looking forward, Yuwell Medical will stay focused on innovation, driving breakthroughs in medical technology, and working with global partners to shape the future of healthcare.